Eli Lilly and Co (LLY)
805.11
-16.08
(-1.96%)
USD |
NYSE |
Jul 26, 16:00
804.60
-0.51
(-0.06%)
After-Hours: 20:00
Eli Lilly Revenue (TTM): 35.93B for March 31, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 35.93B |
December 31, 2023 | 34.12B |
September 30, 2023 | 32.07B |
June 30, 2023 | 29.52B |
March 31, 2023 | 27.69B |
December 31, 2022 | 28.54B |
September 30, 2022 | 29.24B |
June 30, 2022 | 29.07B |
March 31, 2022 | 29.32B |
December 31, 2021 | 28.32B |
September 30, 2021 | 27.76B |
June 30, 2021 | 26.73B |
March 31, 2021 | 25.49B |
December 31, 2020 | 24.54B |
September 30, 2020 | 23.21B |
June 30, 2020 | 22.95B |
March 31, 2020 | 23.09B |
December 31, 2019 | 22.32B |
September 30, 2019 | 21.84B |
June 30, 2019 | 21.67B |
March 31, 2019 | 21.62B |
December 31, 2018 | 21.49B |
September 30, 2018 | 19.12B |
June 30, 2018 | 19.47B |
March 31, 2018 | 19.71B |
Date | Value |
---|---|
December 31, 2017 | 19.97B |
September 30, 2017 | 22.47B |
June 30, 2017 | 22.00B |
March 31, 2017 | 21.59B |
December 31, 2016 | 21.22B |
September 30, 2016 | 20.84B |
June 30, 2016 | 20.61B |
March 31, 2016 | 20.18B |
December 31, 2015 | 19.96B |
September 30, 2015 | 19.70B |
June 30, 2015 | 19.62B |
March 31, 2015 | 19.58B |
December 31, 2014 | 19.62B |
September 30, 2014 | 20.30B |
June 30, 2014 | 21.20B |
March 31, 2014 | 22.19B |
December 31, 2013 | 23.11B |
September 30, 2013 | 23.26B |
June 30, 2013 | 22.93B |
March 31, 2013 | 22.60B |
December 31, 2012 | 22.60B |
September 30, 2012 | 22.69B |
June 30, 2012 | 23.40B |
March 31, 2012 | 24.05B |
December 31, 2011 | 24.29B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
21.84B
Minimum
Sep 2019
35.93B
Maximum
Mar 2024
27.46B
Average
27.76B
Median
Sep 2021
Revenue (TTM) Benchmarks
Amgen Inc | 29.53B |
Biogen Inc | 9.663B |
Vertex Pharmaceuticals Inc | 10.18B |
Viking Therapeutics Inc | -- |
Morphic Holding Inc | -- |